We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
LOKELMA (AstraZeneca Pty Ltd)
Product name
LOKELMA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
206 (255 working days)
Active ingredients
sodium zirconium cyclosilicate hydrate
Registration type
NCE/NBE
Indication
LOKELMA is indicated for the treatment of hyperkalaemia in adult patients.